Kawaljit Kaur

TL;DR: This review will focus on the latest developments and future challenges concerning the structure and biophysics of the T3SS, which consists of structural and nonstructural proteins.

TL;DR: In this article, an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines.

TL;DR: The results show that AZA-9 blocks key RNA-binding residues of HuR and disrupts HuR-RNA interactions in vitro, needed in developing more potent AZa-9 derivatives that could lead to new cancer therapy.

TL;DR: It is shown by CD and NMR spectroscopy that the monomeric form of PrgJ lacks a tertiary structure, and the only well-structured part of Pr gJ is a short α-helix at the C-terminal region from residues 65–82.

TL;DR: Results are an encouraging step to demonstrate that recombinant CRM197 expressed in alternative sources have the potential to replace CRM 197 expressed in C diphtheriae as a source of immunogenic carrier protein for lower cost polysaccharide conjugate vaccines.